STARTUP PROFILE

Mave Health

COUNTRY
India
FOUNDED
2023
CATEGORY
Consumer Neurotech
Developing a non-invasive tDCS-based brain stimulation platform aimed at improving focus, stress regulation, emotional control, and sleep by targeting prefrontal cortex function.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

Mave Health

news and updates

  • 18 Mar 2026: Mave Health raised a $2.1M seed round led by Blume Ventures, with Stanford Angels, Dhaval Shroff and Raymond Russell participating. That brings total funding to just under $3M.
  • 18 Mar 2026: Mave opened pre-orders for its tDCS headset at $495 with no subscription, with shipping from April 2026 in the US and India. The 1 to 2 mA device is designed for 20-minute daily sessions and sold as a non-medical lifestyle product. The company has not published clinical trials.
•
Neurofounders Insights
$   Funding   -
Seed
MODALITY
tDCS/tES
FORM FACTOR
Headset/cap
INTERFACE DEPTH
Non-invasive
INDICATION
Wellness
TARGET USER
Consumers
REGULATORY STAGE
Non-medical
Mave sits in the consumer tDCS wellness category, targeting focus, stress regulation, emotional control, and sleep through prefrontal stimulation. It is best understood as a lifestyle neurostimulation product rather than a regulated mental-health therapy.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
No items found.
Articles featuring
Mave Health